Corbus Pharmaceuticals (NasdaqCM:CRBP) FY Conference February 25, 2026 03:20 PM ET Speaker0Afternoon, everyone, welcome back to Oppenheimer's 36th Annual Healthcare Conference. I'm Jeff Jones, one of the biotech analysts on the team here, I'm delighted to welcome Yuval Cohen, CEO of Corbus Pharmaceuticals. Well, I can talk. Good afternoon, Yuval. How are you?Speaker1Hello, Jeff. How are you?Speaker0Good. Thank you for joining us today. It's, you know, a great way to kick off an exciting 2026 for you guys.Sp ...

Group 1 - Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira to its board of directors, marking the first additions since a significant management shake-up in 2025 [1] - The company replaced its CEO and overhauled the board, appointing Lars Rebien Sorensen as board chairman, who also chairs the Novo Nordisk Foundation, consolidating power in a dual role [1] - Jan van de Winkel is the co-founder and CEO of Genmab, while Ramona Sequeira previously served as President of the Global Portfolio Division at Takeda Pharmaceutical Company Limited from 2022 to 2025 [1]

Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion. This growth was fueled by a 54% surge in sales of its proprietary medicines, most notably Abkinley, which generated $468 million, which was a 67% year-over-year increase. The company also benefited from the continued success of its royalty portfolio, particularly Darzalex, which is projected to reach net sales of up to ...

Core Viewpoint - The health care sector has several oversold stocks that present potential buying opportunities for undervalued companies [1]. Group 1: Oversold Stocks - The Relative Strength Index (RSI) is a momentum indicator that helps traders assess stock performance, with an RSI below 30 indicating that a stock is typically considered oversold [1]. - A list of major oversold stocks in the health care sector includes companies with an RSI near or below 30 [2]. Group 2: Company Specifics - Schrodinger Inc (NASDAQ:SDGR) has an RSI value of 29.9, with its stock price falling approximately 28% over the past month, reaching a 52-week low of $11.15 [3]. - On February 18, Schrodinger reported inducement grants under Nasdaq Listing Rule 5635(c)(4) [3]. - Schrodinger's shares rose by 1.6% to close at $11.81 on Wednesday, with an Edge Stock Rating momentum score of 2.78 [3].

Core Viewpoint - Genmab A/S is highlighted as a high-growth international stock, with a strong buy rating and a price target of $39 following significant sales growth of DARZALEX in 2025 [1]. Group 1: Sales Performance - In 2025, worldwide net sales of DARZALEX reached $14.351 billion, an increase from $11.670 billion in 2024, representing a growth of approximately 22.9% [2]. - The US contributed over half of the sales, amounting to around $8.266 billion, while the rest of the world accounted for $6.085 billion [2]. Group 2: Royalty Revenue - Genmab does not sell DARZALEX directly but earns royalties from Johnson & Johnson, receiving $2.219 billion in total royalty revenue during the first nine months of 2025, up from $1.802 billion in the same period of 2024, marking a 23% year-over-year increase [4]. - Management had initially estimated full-year DARZALEX royalties to be between $2.3 billion and $2.4 billion, based on projected net sales of $13.7 billion to $14.1 billion, but actual sales exceeded expectations, indicating royalties will likely surpass $2.4 billion [5]. Group 3: Company Overview - Genmab A/S is a Denmark-based biotechnology company focused on developing antibody therapeutics for cancer treatment, co-developing drugs like DARZALEX, Kesimpta, and TEPEZZA, and earning royalties through licenses to partners such as Johnson & Johnson [6].

Core Insights - AbbVie experienced a sales growth of approximately 8.5% year over year in 2025, despite facing biosimilar erosion of its flagship drug Humira, which lost exclusivity in early 2023 [2] - For 2026, AbbVie projects revenues to reach $67 billion, indicating a growth of about 9.5% over 2025, primarily driven by newer immunology drugs Rinvoq and Skyrizi [3][10] Immunology Segment - AbbVie expects to generate over $31 billion from sales of Skyrizi and Rinvoq in 2026, with both drugs anticipated to grow more than 20% year over year [4][5][10] - Skyrizi is projected to achieve sales of approximately $21.5 billion, while Rinvoq is expected to reach around $10.1 billion [5] Neuroscience Segment - The neuroscience franchise is expected to contribute $12.5 billion in sales for 2026, reflecting a 16% growth over 2025 [7][10] - AbbVie anticipates Vyalev, a new Parkinson's disease therapy, to surpass $1 billion in global sales [7][10] - The company is also seeking FDA approval for a new oral therapy for Parkinson's disease, tavapadon, which could further enhance its neuroscience portfolio [8] Oncology Segment - AbbVie faces near-term challenges in its oncology segment, particularly with the J&J-partnered Imbruvica, which is expected to see sales decline to $2.2 billion, a drop of over 23% from 2025 [11][12][10] - Despite this decline, other oncology drugs are expected to partially offset the impact, including Venclexta, Epkinly, Elahere, and Emrelis [12] Valuation and Market Performance - AbbVie shares have underperformed the industry over the past year and are currently trading at a P/E ratio of 15.25, below the industry average of 18.75 [13][14] - The bottom-line estimate per share for 2026 and 2027 has seen a decline in the past 30 days [16]

Core Insights - Genmab A/S (NASDAQ:GMAB) is recognized as a promising healthcare stock priced under $50, with significant sales figures reported for its product DARZALEX, totaling $14.351 billion in worldwide net trade sales for 2025 [1] - The company has received positive price target adjustments from analysts, with H.C. Wainwright setting a target of $39 and BofA adjusting it to $38.50, both maintaining a Buy rating, indicating confidence in Genmab's future performance [2] Company Overview - Genmab A/S is an international biotechnology company focused on developing human antibody therapeutics for cancer and other diseases, with a product pipeline that includes DARZALEX for multiple myeloma, TEPEZZA for thyroid eye disease, and Arzerra for chronic lymphocytic leukemia [3]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]

Core Insights - AbbVie Inc. reported fourth-quarter 2025 adjusted EPS of $2.71, surpassing the Zacks Consensus Estimate of $2.66 and the company's prior guidance of $2.61-$2.65, with earnings increasing over 25% year over year [1][10] - The company's revenues reached $16.62 billion, exceeding the Zacks Consensus Estimate of $16.36 billion, with a year-over-year growth of 10.0% on a reported basis and 9.5% operationally [2][10] Revenue Performance - Key drugs driving revenue included Rinvoq, Skyrizi, Venclexta, and Vraylar, alongside contributions from newer drugs like Ubrelvy, Qulipta, Elahere, and Vyalev, while sales of Humira and Imbruvica declined [3] - Immunology drug Rinvoq generated $2.37 billion in net revenues, up nearly 29%, although it missed the Zacks Consensus Estimate of $2.39 billion [4] - Skyrizi's sales reached $5.01 billion, reflecting a 32% increase and surpassing the Zacks Consensus Estimate of $4.91 billion [5] - Humira's sales fell 26% to $1.25 billion, with U.S. sales down 28% to $897 million, attributed to loss of exclusivity since January 2023, yet it exceeded the Zacks Consensus Estimate of $949 million [6] - Neuroscience portfolio sales rose over 17% to $2.96 billion, driven by Botox Therapeutic and Vraylar, but missed the Zacks Consensus Estimate of $3.00 billion [7] - Oncology franchise sales decreased 2.5% to $1.66 billion, primarily due to declining Imbruvica sales, missing the Zacks Consensus Estimate of $1.72 billion [9] Cost and Financial Outlook - Adjusted SG&A expenses increased 4% year over year to $3.71 billion, while adjusted R&D expenses rose approximately 13% to $2.56 billion [15] - For the full year 2025, AbbVie reported sales growth of 8.6% to $61.16 billion, exceeding the Zacks Consensus Estimate of $60.93 billion, with adjusted EPS of $10.00, down 1% year over year but beating estimates [16] - AbbVie provided guidance for 2026 adjusted EPS in the range of $14.37-$14.57, excluding impacts from proposed acquisitions, with the Zacks Consensus Estimate at $14.32 [17] Market Reaction and Strategic Focus - Despite strong results, AbbVie's shares traded lower in pre-market trading, likely due to underperformance in Rinvoq and oncology drugs [19] - The company is focusing on inorganic growth to strengthen its early-stage pipeline across multiple therapeutic areas, with recent acquisitions impacting near-term earnings [21][22]

Core Viewpoint - AbbVie Inc. is considered one of the best healthcare stocks to buy for 2026, with Goldman Sachs reaffirming a Neutral rating and a price target of $223 ahead of its Q4 2025 earnings and 2026 guidance release [1] Financial Performance - Goldman Sachs projects AbbVie will achieve $67.1 billion in revenue for 2026, with $21.3 billion from Skyrizi and $10.4 billion from Rinvoq, alongside an EPS of $14.22, which aligns with consensus expectations [1] - A slight revenue beat is anticipated in Q4, driven by Skyrizi's performance exceeding expectations, while Rinvoq is expected to perform slightly below [2] Business Segments - The Aesthetics business is under continued pressure, while Neurology and Oncology are expected to show steady results [2] - AbbVie has a high P/E ratio of 168.95, reflecting strong growth expectations, supported by a dividend yield of 3.09% [2] Clinical Trials - AbbVie reported mixed results in the phase 3 Lymphoma trial for epcoritamab, showing improved progression-free survival but failing to meet the overall survival endpoint [3] - The adverse events observed were consistent with the known safety profile of the candidate drug [3] Strategic Response - AbbVie and its partner Genmab are investigating potential factors that may have negatively influenced the trial results, including the impact of the COVID-19 pandemic and the availability of new anti-lymphoma therapies [4] Company Overview - AbbVie is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for complex health issues, specializing in immunology, oncology, neuroscience, and eye care [5]